Incyte
Last updated Jul 27, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
75%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Hematology
- JAK Inhibitor
- Oncology
- Small Molecule
- Dermatology
Highest priority development: FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Novartis.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 75%
Active Signals
10
Investigate Priority
0
Opportunity Score
488
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 27, 2026Score 54Novartis initiates long-term safety study for ruxolitinib and panobinostat combination
Hematology · JAK Inhibitor
- MonitorJul 12, 2026Score 50FDA Approves JAKAFI XR for Incyte Corp.
Hematology · JAK Inhibitor
- MonitorJul 24, 2026Score 49FDA Accepts Supplement for JAKAFI (Ruxolitinib Phosphate) by Incyte
Hematology · JAK Inhibitor
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancerModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - IND Application Reporting: IND Safety ReportsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Clinical trials for medicines: collection, verification and reporting of safety eventsModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera - FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancerModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Incyte right now?
- Which regulatory precedents should Incyte monitor in Hematology and JAK Inhibitor?
- Which pipeline programs should Incyte prioritize for competitive review?
- What signals require immediate investigation for Incyte?
- Summarize the strategic implications of recent developments for Incyte.
- Where is the greatest uncertainty in Incyte's competitive positioning?